2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.
- Ryom L CHIP, Center of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Section 2100, Center for Cardiac, Vascular, Pulmonary and Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
- Cotter A University College Dublin Centre for Experimental Pathogen Host Research, Dublin, Ireland.
- De Miguel R Infectious Diseases Unit, La Paz Hospital, Madrid, Spain.
- Béguelin C Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- Podlekareva D CHIP, Center of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Section 2100, Center for Cardiac, Vascular, Pulmonary and Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
- Arribas JR Infectious Diseases Unit, La Paz Hospital, Madrid, Spain.
- Marzolini C Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel and University of Basel, Basel, Switzerland.
- Mallon P University College Dublin Centre for Experimental Pathogen Host Research, Dublin, Ireland.
- Rauch A Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- Kirk O CHIP, Center of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Section 2100, Center for Cardiac, Vascular, Pulmonary and Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
- Molina JM Department of Infectious Diseases, St Louis and Lariboisière Hospitals, APHP and University of Paris, Paris, France.
- Guaraldi G Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
- Winston A Imperial College London, London, UK.
- Bhagani S Department of Infectious Diseases/HIV Medicine, Royal Free London NHS Trust, Institute of Global Health, University College London, London, UK.
- Cinque P Division of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy.
- Kowalska JD Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
- Collins S HIV i-Base and EATG, London, UK.
- Battegay M Division of Infectious Diseases et Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland.
- 2020-09-05
Published in:
- HIV medicine. - 2020
European AIDS Clinical Society (EACS) Guidelines
HIV
antiretroviral treatment
comorbidities
drug-drug interactions
hepatitis B virus
hepatitis C virus
opportunistic infections
prescribing in elderly patients
English
BACKGROUND
The European AIDS Clinical Society (EACS) Guidelines cover key aspects of HIV management with major updates every two years.
GUIDELINE HIGHLIGHTS
The 2019 Guidelines were extended with a new section focusing on drug-drug interactions and other prescribing issues in people living with HIV (PLWH). The recommendations for treatment-naïve PLWH were updated with four preferred regimens favouring unboosted integrase inhibitors. A two-drug regimen with dolutegravir and lamivudine, and a three-drug regimen including doravirine were also added to the recommended initial regimens. Lower thresholds for hypertension were expanded to all PLWH and for cardiovascular disease prevention, the 10-year predicted risk threshold for consideration of antiretroviral therapy (ART) modification was lowered from 20% to 10%. Frailty and obesity were added as new topics. It was specified to use urine albumin to creatinine ratio to screen for glomerular disease and urine protein to creatinine ratio for tubular diseases, and thresholds were streamlined with the Kidney Disease: Improving Global Outcomes (KDIGO) recommendations. Hepatitis C virus (HCV) treatment recommendations were split into preferred and alternative treatment options. The algorithm for management of recently acquired HCV infection was updated and includes recommendations for early chronic infection management. Treatment of resistant tuberculosis (TB) was streamlined with the World Health Organization (WHO) recommendations, and new tables on immune reconstitution inflammatory syndrome, on when to start ART in the presence of opportunistic infections and on TB drug dosing were included.
CONCLUSIONS
The EACS Guidelines underwent major revisions of all sections in 2019. They are available in four different formats including a new interactive web-based version and are translated into Chinese, French, German, Japanese, Portuguese, Russian and Spanish.
The European AIDS Clinical Society (EACS) Guidelines cover key aspects of HIV management with major updates every two years.
GUIDELINE HIGHLIGHTS
The 2019 Guidelines were extended with a new section focusing on drug-drug interactions and other prescribing issues in people living with HIV (PLWH). The recommendations for treatment-naïve PLWH were updated with four preferred regimens favouring unboosted integrase inhibitors. A two-drug regimen with dolutegravir and lamivudine, and a three-drug regimen including doravirine were also added to the recommended initial regimens. Lower thresholds for hypertension were expanded to all PLWH and for cardiovascular disease prevention, the 10-year predicted risk threshold for consideration of antiretroviral therapy (ART) modification was lowered from 20% to 10%. Frailty and obesity were added as new topics. It was specified to use urine albumin to creatinine ratio to screen for glomerular disease and urine protein to creatinine ratio for tubular diseases, and thresholds were streamlined with the Kidney Disease: Improving Global Outcomes (KDIGO) recommendations. Hepatitis C virus (HCV) treatment recommendations were split into preferred and alternative treatment options. The algorithm for management of recently acquired HCV infection was updated and includes recommendations for early chronic infection management. Treatment of resistant tuberculosis (TB) was streamlined with the World Health Organization (WHO) recommendations, and new tables on immune reconstitution inflammatory syndrome, on when to start ART in the presence of opportunistic infections and on TB drug dosing were included.
CONCLUSIONS
The EACS Guidelines underwent major revisions of all sections in 2019. They are available in four different formats including a new interactive web-based version and are translated into Chinese, French, German, Japanese, Portuguese, Russian and Spanish.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1111/hiv.12878
- PMID 32885559
- Persistent URL
- https://folia.unifr.ch/global/documents/33372
Statistics
Document views: 18
File downloads:
- fulltext.pdf: 0